Agendia BV Release: Value Of Breast Cancer Molecular Subtyping Documented By Independent Study Comparing Genomic Tests At American Society of Clinical Oncology 2014 Meeting
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--There are substantial differences between the results provided by Agendia’s next-generation breast cancer tests and more limited results from the first-generation, 21-gene assay, according to findings presented at the recently concluded annual meeting of the American Society of Clinical Oncology (ASCO).
Help employers find you! Check out all the jobs and post your resume.